Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors

Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors

Triple-negative breast cancer (TNBC) is primarily treated via chemotherapy; in parallel, efforts are made to introduce immunotherapies into TNBC treatment. CD4+ TNFR2+ lymphocytes were reported as Tregs that contribute to tumor progression. However, our published study indicated that TNFR2+ tumor-in...

Full description

Bibliographic Details
Main Authors: Tamir Baram, Nofar Erlichman, Maya Dadiani, Nora Balint-Lahat, Anya Pavlovski, Tsipi Meshel, Dana Morzaev-Sulzbach, Einav Nili Gal-Yam, Iris Barshack, Adit Ben-Baruch
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cells
Subjects:
CD4+ lymphocytes
CD8+ lymphocytes
forkhead box P3 (FOXP3)
programmed cell death protein 1 (PD-1)
splenocytes
triple-negative breast cancer (TNBC)
Online Access:https://www.mdpi.com/2073-4409/10/6/1429

Internet

https://www.mdpi.com/2073-4409/10/6/1429

Similar Items